Ceftibuten—in-vitro activity against respiratory pathogens, β-lactamase stability and mechanism of action

Abstract
The in-vitro activity of ceftibuten against respiratory pathogenic bacteria was studied and compared with that of other oral β-lactam agents. Ceftibuten displayed high activity against Haemophilus influenzae and Branhamella catarrhalis. There was reduced activity against Streptococcus pneumoniae (MIC90 16 mg/l). The protein binding of ceftibuten was 77% and the primary target site PBP 3. A high degree of stability to β-lactamase hydrolysis was observed.